Abstract
Abstract
Background
There is no appropriate tool to predict recombinant human growth hormone (rhGH) response before therapy initiation in short-stature children in late puberty. The current study aimed to explore the associations between magnetic resonance imaging (MRI) stages of the knee growth plates and rhGH response in short-stature children in late puberty.
Methods
In this prospective cohort study, short-stature children in late puberty were treated with rhGH and followed up for 6 months. We proposed a novel knee MRI staging system according to the growth plate states of distal femurs or proximal tibias and divided the participants into three groups: unclosed growth plate group, marginally closed growth plate group, and nearly closed growth plate group. The primary outcomes were height gain and growth velocity (GV), which were assessed three months later.
Results
Fifty participants were enrolled, including 23 boys and 27 girls. GV and height gain after 6 months of rhGH therapy decreased successively in the three groups with an increased degree of growth plate fusion, especially when grouped by proximal tibias (GV1-3 mon from 9.38 to 6.08 to 4.56 cm/year, GV4-6 mon from 6.75 to 4.92 to 3.25 cm/year, and height gain from 4.03 to 2.75 to 1.95 cm, all P < 0.001). Moreover, the MRI stages of growth plates independently served as a significant variable for GV and height gain after therapy, especially when grouped by proximal tibias (all P < 0.01).
Conclusion
The MRI staging method is expected to be an effective tool for predicting rhGH response before therapy initiation in short-stature children in late puberty.
Graphical abstract
Funder
the CAMS Innovation Fund for Medical Science
High-level Hospital Construction Project of Guangdong Provincial People's Hospital
Publisher
Springer Science and Business Media LLC
Subject
Pediatrics, Perinatology and Child Health
Reference45 articles.
1. Ranke MB, Wit JM. Growth hormone - past, present and future. Nat Rev Endocrinol. 2018;14:285–300.
2. Cheng RQ, Ying YQ, Qiu ZQ, Fu JF, Gong CX, Yang YL, et al. Early recombinant human growth hormone treatment improves mental development and alleviates deterioration of motor function in infants and young children with Prader-Willi syndrome. World J Pediatr. 2023;19:438–49.
3. Bamba V, Kanakatti SR. Approach to the patient: safety of growth hormone replacement in children and adolescents. J Clin Endocrinol Metab. 2022;107:847–61.
4. Soliman AT, Elawwa A, Itani M, Jour C, De Sanctis V. Responses to growth hormone (GH) therapy in short children with normal GH secretion and no bone age delay: an analysis of potential factors affecting their response to rhGH therapy. A controlled study. Acta Biomed. 2019;90:43–51.
5. Sánchez Malo MJ, Hidalgo Sanz J, Hernández Tejedor C, García Ventura M, Ferrer Lozano M, Labarta Aizpún JI, et al. Growth hormone deficit: influence of puberty on the response to treatment. An Pediatr (Engl Ed). 2022;96:221–9 (in Spanish).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献